Skip to main content
Top
Published in: Supportive Care in Cancer 9/2014

01-09-2014 | Original Article

The impact of bone mineral density testing, fracture assessment, and osteoporosis education in men treated by androgen deprivation for prostate cancer: a pilot study

Authors: Michelle Nadler, Shabbir Alibhai, Pamela Catton, Charles Catton, Jennifer Jones

Published in: Supportive Care in Cancer | Issue 9/2014

Login to get access

Abstract

Purpose

Men receiving androgen deprivation therapy for prostate cancer have low knowledge of osteoporosis (OP) and engage in few healthy bone behaviors (HBBs). A multicomponent intervention was piloted in this population. Changes in OP knowledge, self-efficacy, health beliefs, and engagement in HBBs were evaluated.

Methods

A pre-post pilot study was performed in a convenience sample of men recruited from the Princess Margaret Cancer Centre. Men were sent personalized letters explaining their dual x-ray absorptiometry (DXA) results and fracture risk assessment with an OP-related education booklet. Participants completed questionnaires assessing OP knowledge, self-efficacy, health beliefs, and current engagement in HBBs at baseline (T1) and 3 months post-intervention (T2). Paired t tests and McNemar’s test were used to assess changes in outcomes.

Results

A total of 148 men completed the study. There was an increase in OP knowledge (9.7 ± 4.3 to 11.4 ± 3.3, p < 0.0001) and feelings of susceptibility (16.5 ± 4.3 to 17.4 ± 4.7, p = 0.015), but a decrease in total self-efficacy (86.3 ± 22.9 to 81.0 ± 27.6, p = 0.007) from baseline to post-intervention. Men made appropriate changes in their overall daily calcium intake (p ≤ 0.001), and there was uptake of vitamin D supplementation from 44 % (n = 65) to 68 % (n = 99) (p < 0.0001). Men with bone loss (osteopenia or OP) had a greater change in susceptibility (1.9 ± 4.3 vs. −0.22 ± 4.2, p = 0.005) compared to men with normal bone density.

Conclusions

Our results provide preliminary evidence that a multicomponent intervention such as the one described can lead to increased knowledge and feelings of susceptibility regarding OP and can enhance uptake of some HBBs.
Literature
1.
go back to reference D'Amico AV, Chen MH, Renshaw AA, Loffredo M, Kantoff PW (2008) Androgen suppression and radiation vs radiation alone for prostate cancer: a randomized trial. JAMA 299(3):289–295PubMed D'Amico AV, Chen MH, Renshaw AA, Loffredo M, Kantoff PW (2008) Androgen suppression and radiation vs radiation alone for prostate cancer: a randomized trial. JAMA 299(3):289–295PubMed
2.
go back to reference Roach M 3rd, Bae K, Speight J, Wolkov HB, Rubin P, Lee RJ et al (2008) Short-term neoadjuvant androgen deprivation therapy and external-beam radiotherapy for locally advanced prostate cancer: long-term results of RTOG 8610. J Clin Oncol 26(4):585–591PubMedCrossRef Roach M 3rd, Bae K, Speight J, Wolkov HB, Rubin P, Lee RJ et al (2008) Short-term neoadjuvant androgen deprivation therapy and external-beam radiotherapy for locally advanced prostate cancer: long-term results of RTOG 8610. J Clin Oncol 26(4):585–591PubMedCrossRef
3.
go back to reference Saylor PJ, Morton RA, Hancock ML, Barnette KG, Steiner MS, Smith MR (2011) Factors associated with vertebral fractures in men treated with androgen deprivation therapy for prostate cancer. J Urol 186(2):482–486PubMedCentralPubMedCrossRef Saylor PJ, Morton RA, Hancock ML, Barnette KG, Steiner MS, Smith MR (2011) Factors associated with vertebral fractures in men treated with androgen deprivation therapy for prostate cancer. J Urol 186(2):482–486PubMedCentralPubMedCrossRef
5.
go back to reference American Cancer S. Cancer Facts & Figures 2010. Atlanta: American Cancer Society American Cancer S. Cancer Facts & Figures 2010. Atlanta: American Cancer Society
6.
go back to reference Saylor PJ, Keating NL, Smith MR (2009) Prostate cancer survivorship: prevention and treatment of the adverse effects of androgen deprivation therapy. J Gen Intern Med 24(Suppl 2):S389–S394PubMedCrossRef Saylor PJ, Keating NL, Smith MR (2009) Prostate cancer survivorship: prevention and treatment of the adverse effects of androgen deprivation therapy. J Gen Intern Med 24(Suppl 2):S389–S394PubMedCrossRef
7.
go back to reference Alibhai SM, Gogov S, Allibhai Z (2006) Long-term side effects of androgen deprivation therapy in men with non-metastatic prostate cancer: a systematic literature review. Crit Rev Oncol Hematol 60(3):201–215PubMedCrossRef Alibhai SM, Gogov S, Allibhai Z (2006) Long-term side effects of androgen deprivation therapy in men with non-metastatic prostate cancer: a systematic literature review. Crit Rev Oncol Hematol 60(3):201–215PubMedCrossRef
8.
go back to reference Alibhai SM, Duong-Hua M, Cheung AM, Sutradhar R, Warde P, Fleshner NE et al (2010) Fracture types and risk factors in men with prostate cancer on androgen deprivation therapy: a matched cohort study of 19,079 men. J Urol 184(3):918–923PubMedCrossRef Alibhai SM, Duong-Hua M, Cheung AM, Sutradhar R, Warde P, Fleshner NE et al (2010) Fracture types and risk factors in men with prostate cancer on androgen deprivation therapy: a matched cohort study of 19,079 men. J Urol 184(3):918–923PubMedCrossRef
9.
go back to reference Gralow JR, Biermann JS, Farooki A, Fornier MN, Gagel RF, Kumar RN et al (2009) NCCN task force report: bone health in cancer care. J Nat Compr Cancer Netw 7(Suppl 3):S1–S32, quiz S3-5 Gralow JR, Biermann JS, Farooki A, Fornier MN, Gagel RF, Kumar RN et al (2009) NCCN task force report: bone health in cancer care. J Nat Compr Cancer Netw 7(Suppl 3):S1–S32, quiz S3-5
10.
go back to reference Michaud LB (2010) Managing cancer treatment-induced bone loss and osteoporosis in patients with breast or prostate cancer. Am J Health Syst Pharm 67(7 Suppl 3):S20–S30, quiz S1-3PubMedCrossRef Michaud LB (2010) Managing cancer treatment-induced bone loss and osteoporosis in patients with breast or prostate cancer. Am J Health Syst Pharm 67(7 Suppl 3):S20–S30, quiz S1-3PubMedCrossRef
11.
go back to reference D'Alesio V, Salvig BE, Fourakre TN (2011) Evaluation of osteoporosis risk assessment in veterans receiving androgen-deprivation therapy. Consult Pharm 26(1):43–47PubMedCrossRef D'Alesio V, Salvig BE, Fourakre TN (2011) Evaluation of osteoporosis risk assessment in veterans receiving androgen-deprivation therapy. Consult Pharm 26(1):43–47PubMedCrossRef
12.
go back to reference Shahinian VB, Kuo YF, Freeman JL, Goodwin JS (2005) Risk of fracture after androgen deprivation for prostate cancer. N Engl J Med 352(2):154–164PubMedCrossRef Shahinian VB, Kuo YF, Freeman JL, Goodwin JS (2005) Risk of fracture after androgen deprivation for prostate cancer. N Engl J Med 352(2):154–164PubMedCrossRef
13.
go back to reference Greenspan SL, Coates P, Sereika SM, Nelson JB, Trump DL, Resnick NM (2005) Bone loss after initiation of androgen deprivation therapy in patients with prostate cancer. J Clin Endocrinol Metab 90(12):6410–6417PubMedCrossRef Greenspan SL, Coates P, Sereika SM, Nelson JB, Trump DL, Resnick NM (2005) Bone loss after initiation of androgen deprivation therapy in patients with prostate cancer. J Clin Endocrinol Metab 90(12):6410–6417PubMedCrossRef
14.
go back to reference Israeli RS, Ryan CW, Jung LL (2008) Managing bone loss in men with locally advanced prostate cancer receiving androgen deprivation therapy. J Urol 179(2):414–423PubMedCrossRef Israeli RS, Ryan CW, Jung LL (2008) Managing bone loss in men with locally advanced prostate cancer receiving androgen deprivation therapy. J Urol 179(2):414–423PubMedCrossRef
15.
go back to reference Serpa Neto A, Tobias-Machado M, Esteves MA, Senra MD, Wroclawski ML, Fonseca FL et al (2010) A systematic review and meta-analysis of bone metabolism in prostate adenocarcinoma. BMC Urol 10:9PubMedCentralPubMedCrossRef Serpa Neto A, Tobias-Machado M, Esteves MA, Senra MD, Wroclawski ML, Fonseca FL et al (2010) A systematic review and meta-analysis of bone metabolism in prostate adenocarcinoma. BMC Urol 10:9PubMedCentralPubMedCrossRef
16.
go back to reference Lattouf JB, Saad F (2010) Bone complications of androgen deprivation therapy: screening, prevention, and treatment. Curr Opin Urol 20(3):247–252PubMedCrossRef Lattouf JB, Saad F (2010) Bone complications of androgen deprivation therapy: screening, prevention, and treatment. Curr Opin Urol 20(3):247–252PubMedCrossRef
17.
go back to reference Taylor LG, Canfield SE, Du XL (2009) Review of major adverse effects of androgen-deprivation therapy in men with prostate cancer. Cancer 115(11):2388–2399PubMedCrossRef Taylor LG, Canfield SE, Du XL (2009) Review of major adverse effects of androgen-deprivation therapy in men with prostate cancer. Cancer 115(11):2388–2399PubMedCrossRef
18.
go back to reference Fink HA, Ensrud KE, Nelson DB, Kerani RP, Schreiner PJ, Zhao Y et al (2003) Disability after clinical fracture in postmenopausal women with low bone density: the fracture intervention trial (FIT). Osteoporos Int 14(1):69–76PubMedCrossRef Fink HA, Ensrud KE, Nelson DB, Kerani RP, Schreiner PJ, Zhao Y et al (2003) Disability after clinical fracture in postmenopausal women with low bone density: the fracture intervention trial (FIT). Osteoporos Int 14(1):69–76PubMedCrossRef
19.
go back to reference Oefelein MG, Ricchiuti V, Conrad W, Resnick MI (2002) Skeletal fractures negatively correlate with overall survival in men with prostate cancer. J Urol 168(3):1005–1007PubMedCrossRef Oefelein MG, Ricchiuti V, Conrad W, Resnick MI (2002) Skeletal fractures negatively correlate with overall survival in men with prostate cancer. J Urol 168(3):1005–1007PubMedCrossRef
20.
go back to reference Ali NS, Shonk C, El-Sayed MS (2009) Bone health in men: influencing factors. Am J Health Behav 33(2):213–222PubMedCrossRef Ali NS, Shonk C, El-Sayed MS (2009) Bone health in men: influencing factors. Am J Health Behav 33(2):213–222PubMedCrossRef
21.
go back to reference Hamdy RC, Baim S, Broy SB, Lewiecki EM, Morgan SL, Tanner SB et al (2010) Algorithm for the management of osteoporosis. South Med J 103(10):1009–1015, quiz 16PubMedCrossRef Hamdy RC, Baim S, Broy SB, Lewiecki EM, Morgan SL, Tanner SB et al (2010) Algorithm for the management of osteoporosis. South Med J 103(10):1009–1015, quiz 16PubMedCrossRef
22.
go back to reference Tosteson AN, Melton LJ 3rd, Dawson-Hughes B, Baim S, Favus MJ, Khosla S et al (2008) Cost-effective osteoporosis treatment thresholds: the United States perspective. Osteoporos Int 19(4):437–447PubMedCentralPubMedCrossRef Tosteson AN, Melton LJ 3rd, Dawson-Hughes B, Baim S, Favus MJ, Khosla S et al (2008) Cost-effective osteoporosis treatment thresholds: the United States perspective. Osteoporos Int 19(4):437–447PubMedCentralPubMedCrossRef
23.
go back to reference Papaioannou A, Morin S, Cheung AM, Atkinson S, Brown JP, Feldman S et al (2010) 2010 clinical practice guidelines for the diagnosis and management of osteoporosis in Canada: summary. CMAJ 182(17):1864–1873PubMedCentralPubMedCrossRef Papaioannou A, Morin S, Cheung AM, Atkinson S, Brown JP, Feldman S et al (2010) 2010 clinical practice guidelines for the diagnosis and management of osteoporosis in Canada: summary. CMAJ 182(17):1864–1873PubMedCentralPubMedCrossRef
24.
go back to reference Duncan GG, Corbett T, Lukka H, Warde P, Pickles T (2006) GU radiation oncologists consensus on bone loss from androgen deprivation. Can J Urol 13(1):2962–2966PubMed Duncan GG, Corbett T, Lukka H, Warde P, Pickles T (2006) GU radiation oncologists consensus on bone loss from androgen deprivation. Can J Urol 13(1):2962–2966PubMed
25.
go back to reference Adler RA (2011) Management of osteoporosis in men on androgen deprivation therapy. Maturitas 68(2):143–147PubMedCrossRef Adler RA (2011) Management of osteoporosis in men on androgen deprivation therapy. Maturitas 68(2):143–147PubMedCrossRef
26.
go back to reference Ito K, Elkin EB, Girotra M, Morris MJ (2010) Cost-effectiveness of fracture prevention in men who receive androgen deprivation therapy for localized prostate cancer. Ann Intern Med 152(10):621–629PubMedCrossRef Ito K, Elkin EB, Girotra M, Morris MJ (2010) Cost-effectiveness of fracture prevention in men who receive androgen deprivation therapy for localized prostate cancer. Ann Intern Med 152(10):621–629PubMedCrossRef
27.
go back to reference Bischoff-Ferrari HA, Dawson-Hughes B, Staehelin HB, Orav JE, Stuck AE, Theiler R et al (2009) Fall prevention with supplemental and active forms of vitamin D: a meta-analysis of randomised controlled trials. BMJ 339:b3692PubMedCentralPubMedCrossRef Bischoff-Ferrari HA, Dawson-Hughes B, Staehelin HB, Orav JE, Stuck AE, Theiler R et al (2009) Fall prevention with supplemental and active forms of vitamin D: a meta-analysis of randomised controlled trials. BMJ 339:b3692PubMedCentralPubMedCrossRef
28.
go back to reference Sherrington C, Whitney JC, Lord SR, Herbert RD, Cumming RG, Close JC (2008) Effective exercise for the prevention of falls: a systematic review and meta-analysis. J Am Geriatr Soc 56(12):2234–2243PubMedCrossRef Sherrington C, Whitney JC, Lord SR, Herbert RD, Cumming RG, Close JC (2008) Effective exercise for the prevention of falls: a systematic review and meta-analysis. J Am Geriatr Soc 56(12):2234–2243PubMedCrossRef
29.
go back to reference Galvao DA, Taaffe DR, Spry N, Joseph D, Newton RU (2010) Combined resistance and aerobic exercise program reverses muscle loss in men undergoing androgen suppression therapy for prostate cancer without bone metastases: a randomized controlled trial. J Clin Oncol 28(2):340–347PubMedCrossRef Galvao DA, Taaffe DR, Spry N, Joseph D, Newton RU (2010) Combined resistance and aerobic exercise program reverses muscle loss in men undergoing androgen suppression therapy for prostate cancer without bone metastases: a randomized controlled trial. J Clin Oncol 28(2):340–347PubMedCrossRef
30.
go back to reference Alibhai SM, Yun L, Cheung AM, Paszat L (2012) Screening for osteoporosis in men receiving androgen deprivation therapy. JAMA 307(3):255–256PubMedCrossRef Alibhai SM, Yun L, Cheung AM, Paszat L (2012) Screening for osteoporosis in men receiving androgen deprivation therapy. JAMA 307(3):255–256PubMedCrossRef
31.
go back to reference Al-Shamsi HO, Lau AN, Malik K, Alamri A, Ioannidis G, Corbett T et al (2012) The current practice of screening, prevention, and treatment of androgen-deprivation-therapy induced osteoporosis in patients with prostate cancer. J Oncol 2012:958596PubMedCentralPubMedCrossRef Al-Shamsi HO, Lau AN, Malik K, Alamri A, Ioannidis G, Corbett T et al (2012) The current practice of screening, prevention, and treatment of androgen-deprivation-therapy induced osteoporosis in patients with prostate cancer. J Oncol 2012:958596PubMedCentralPubMedCrossRef
32.
go back to reference Nadler M, Alibhai S, Catton P, Catton C, To MJ, Jones JM (2013) Osteoporosis knowledge, health beliefs, and healthy bone behaviours in patients on androgen-deprivation therapy (ADT) for prostate cancer. BJU Int 118(8):1301–1309CrossRef Nadler M, Alibhai S, Catton P, Catton C, To MJ, Jones JM (2013) Osteoporosis knowledge, health beliefs, and healthy bone behaviours in patients on androgen-deprivation therapy (ADT) for prostate cancer. BJU Int 118(8):1301–1309CrossRef
33.
go back to reference Walker LM, Tran S, Wassersug RJ, Thomas B, Robinson JW (2012) Patients and partners lack knowledge of androgen deprivation therapy side effects. Urol Oncol Walker LM, Tran S, Wassersug RJ, Thomas B, Robinson JW (2012) Patients and partners lack knowledge of androgen deprivation therapy side effects. Urol Oncol
34.
go back to reference Panju AH, Breunis H, Cheung AM, Leach M, Fleshner N, Warde P et al (2009) Management of decreased bone mineral density in men starting androgen-deprivation therapy for prostate cancer. BJU Int 103(6):753–757PubMedCrossRef Panju AH, Breunis H, Cheung AM, Leach M, Fleshner N, Warde P et al (2009) Management of decreased bone mineral density in men starting androgen-deprivation therapy for prostate cancer. BJU Int 103(6):753–757PubMedCrossRef
36.
go back to reference Rosenstock IM, Strecher VJ, Becker MH (1988) Social learning theory and the Health Belief Model. Health Educ Q 15(2):175–183PubMedCrossRef Rosenstock IM, Strecher VJ, Becker MH (1988) Social learning theory and the Health Belief Model. Health Educ Q 15(2):175–183PubMedCrossRef
37.
go back to reference Harrison JA, Mullen PD, Green LW (1992) A meta-analysis of studies of the Health Belief Model with adults. Health Educ Res 7(1):107–116PubMedCrossRef Harrison JA, Mullen PD, Green LW (1992) A meta-analysis of studies of the Health Belief Model with adults. Health Educ Res 7(1):107–116PubMedCrossRef
38.
go back to reference Painter JE, Borba CP, Hynes M, Mays D, Glanz K (2008) The use of theory in health behavior research from 2000 to 2005: a systematic review. Ann Behav Med 35(3):358–362PubMedCrossRef Painter JE, Borba CP, Hynes M, Mays D, Glanz K (2008) The use of theory in health behavior research from 2000 to 2005: a systematic review. Ann Behav Med 35(3):358–362PubMedCrossRef
40.
go back to reference Laslett LL, Lynch J, Sullivan TR, McNeil JD (2011) Osteoporosis education improves osteoporosis knowledge and dietary calcium: comparison of a 4 week and a one-session education course. Int J Rheum Dis 14(3):239–247PubMedCrossRef Laslett LL, Lynch J, Sullivan TR, McNeil JD (2011) Osteoporosis education improves osteoporosis knowledge and dietary calcium: comparison of a 4 week and a one-session education course. Int J Rheum Dis 14(3):239–247PubMedCrossRef
41.
go back to reference Francis KL, Matthews BL, Van Mechelen W, Bennell KL, Osborne RH (2009) Effectiveness of a community-based osteoporosis education and self-management course: a wait list controlled trial. Osteoporos Int 20(9):1563–1570PubMedCrossRef Francis KL, Matthews BL, Van Mechelen W, Bennell KL, Osborne RH (2009) Effectiveness of a community-based osteoporosis education and self-management course: a wait list controlled trial. Osteoporos Int 20(9):1563–1570PubMedCrossRef
42.
go back to reference Drieling RL, Ma J, Thiyagarajan S, Stafford RS (2011) An Internet-based osteoporotic fracture risk program: effect on knowledge, attitudes, and behaviors. J Womens Health (Larchmt) 20(12):1895–1907CrossRef Drieling RL, Ma J, Thiyagarajan S, Stafford RS (2011) An Internet-based osteoporotic fracture risk program: effect on knowledge, attitudes, and behaviors. J Womens Health (Larchmt) 20(12):1895–1907CrossRef
43.
go back to reference Werner P (2005) Knowledge about osteoporosis: assessment, correlates and outcomes. Osteoporos Int 16(2):115–127PubMedCrossRef Werner P (2005) Knowledge about osteoporosis: assessment, correlates and outcomes. Osteoporos Int 16(2):115–127PubMedCrossRef
44.
go back to reference Babatunde OT, Himburg SP, Newman FL, Campa A, Dixon Z (2011) Theory-driven intervention improves calcium intake, osteoporosis knowledge, and self-efficacy in community-dwelling older Black adults. J Nutr Educ Behav 43(6):434–440PubMedCrossRef Babatunde OT, Himburg SP, Newman FL, Campa A, Dixon Z (2011) Theory-driven intervention improves calcium intake, osteoporosis knowledge, and self-efficacy in community-dwelling older Black adults. J Nutr Educ Behav 43(6):434–440PubMedCrossRef
45.
go back to reference Aree-Ue S, Pothiban L, Belza B, Sucamvang K, Panuthai S (2006) Osteoporosis preventive behavior in Thai older adults: feasibility and acceptability. J Gerontol Nurs 32(7):23–30PubMed Aree-Ue S, Pothiban L, Belza B, Sucamvang K, Panuthai S (2006) Osteoporosis preventive behavior in Thai older adults: feasibility and acceptability. J Gerontol Nurs 32(7):23–30PubMed
46.
go back to reference Marci CD, Anderson WB, Viechnicki MB, Greenspan SL (2000) Bone mineral densitometry substantially influences health-related behaviors of postmenopausal women. Calcif Tissue Int 66(2):113–118PubMedCrossRef Marci CD, Anderson WB, Viechnicki MB, Greenspan SL (2000) Bone mineral densitometry substantially influences health-related behaviors of postmenopausal women. Calcif Tissue Int 66(2):113–118PubMedCrossRef
47.
go back to reference Brask-Lindemann D, Cadarette SM, Eskildsen P, Abrahamsen B (2011) Osteoporosis pharmacotherapy following bone densitometry: importance of patient beliefs and understanding of DXA results. Osteoporos Int 22(5):1493–1501PubMedCrossRef Brask-Lindemann D, Cadarette SM, Eskildsen P, Abrahamsen B (2011) Osteoporosis pharmacotherapy following bone densitometry: importance of patient beliefs and understanding of DXA results. Osteoporos Int 22(5):1493–1501PubMedCrossRef
48.
go back to reference Doheny MO, Sedlak CA, Estok PJ, Zeller RA (2011) Bone density, health beliefs, and osteoporosis preventing behaviors in men. Orthop Nurs 30(4):266–272PubMedCentralPubMedCrossRef Doheny MO, Sedlak CA, Estok PJ, Zeller RA (2011) Bone density, health beliefs, and osteoporosis preventing behaviors in men. Orthop Nurs 30(4):266–272PubMedCentralPubMedCrossRef
49.
go back to reference Doheny MO, Sedlak CA, Hall RJ, Estok PJ (2010) Structural model for osteoporosis preventing behavior in men. Am J Men's Health 4(4):334–343CrossRef Doheny MO, Sedlak CA, Hall RJ, Estok PJ (2010) Structural model for osteoporosis preventing behavior in men. Am J Men's Health 4(4):334–343CrossRef
50.
go back to reference Patel A, Coates PS, Nelson JB, Trump DL, Resnick NM, Greenspan SL (2003) Does bone mineral density and knowledge influence health-related behaviors of elderly men at risk for osteoporosis? J Clin Densitom 6(4):323–330PubMedCrossRef Patel A, Coates PS, Nelson JB, Trump DL, Resnick NM, Greenspan SL (2003) Does bone mineral density and knowledge influence health-related behaviors of elderly men at risk for osteoporosis? J Clin Densitom 6(4):323–330PubMedCrossRef
51.
go back to reference Davison BJ, Wiens K, Cushing M (2011) Promoting calcium and vitamin D intake to reduce the risk of osteoporosis in men on androgen deprivation therapy for recurrent prostate cancer. Support Care Cancer Davison BJ, Wiens K, Cushing M (2011) Promoting calcium and vitamin D intake to reduce the risk of osteoporosis in men on androgen deprivation therapy for recurrent prostate cancer. Support Care Cancer
52.
go back to reference Ancker JS, Senathirajah Y, Kukafka R, Starren JB (2006) Design features of graphs in health risk communication: a systematic review. J Am Med Inform Assoc 13(6):608–618PubMedCentralPubMedCrossRef Ancker JS, Senathirajah Y, Kukafka R, Starren JB (2006) Design features of graphs in health risk communication: a systematic review. J Am Med Inform Assoc 13(6):608–618PubMedCentralPubMedCrossRef
53.
go back to reference Ancker JS, Chan C, Kukafka R (2009) Interactive graphics for expressing health risks: development and qualitative evaluation. J Health Commun 14(5):461–475PubMedCrossRef Ancker JS, Chan C, Kukafka R (2009) Interactive graphics for expressing health risks: development and qualitative evaluation. J Health Commun 14(5):461–475PubMedCrossRef
54.
go back to reference Lewiecki EM (2010) Risk communication and shared decision making in the care of patients with osteoporosis. J Clin Densitom 13(4):335–345PubMedCrossRef Lewiecki EM (2010) Risk communication and shared decision making in the care of patients with osteoporosis. J Clin Densitom 13(4):335–345PubMedCrossRef
55.
go back to reference Lewiecki EM (2011) The role of risk communication in the care of osteoporosis. Curr Osteoporos Rep 9(3):141–148PubMedCrossRef Lewiecki EM (2011) The role of risk communication in the care of osteoporosis. Curr Osteoporos Rep 9(3):141–148PubMedCrossRef
56.
go back to reference Ailinger RL, Lasus H, Braun MA (2003) Revision of the facts on osteoporosis quiz. Nurs Res 52(3):198–201PubMedCrossRef Ailinger RL, Lasus H, Braun MA (2003) Revision of the facts on osteoporosis quiz. Nurs Res 52(3):198–201PubMedCrossRef
57.
go back to reference Gaines JM, Marx KA, Narrett M, Caudill J, Landsman J, Parrish JM (2011) Validation of the male osteoporosis knowledge quiz. Am J Men's Health 5(1):78–83CrossRef Gaines JM, Marx KA, Narrett M, Caudill J, Landsman J, Parrish JM (2011) Validation of the male osteoporosis knowledge quiz. Am J Men's Health 5(1):78–83CrossRef
58.
go back to reference Horan ML, Kim KK, Gendler P, Froman RD, Patel MD (1998) Development and evaluation of the Osteoporosis Self-Efficacy Scale. Res Nurs Health 21(5):395–403PubMedCrossRef Horan ML, Kim KK, Gendler P, Froman RD, Patel MD (1998) Development and evaluation of the Osteoporosis Self-Efficacy Scale. Res Nurs Health 21(5):395–403PubMedCrossRef
59.
go back to reference Kim KK, Horan ML, Gendler P, Patel MK (1991) Development and evaluation of the Osteoporosis Health Belief Scale. Res Nurs Health 14(2):155–163PubMedCrossRef Kim KK, Horan ML, Gendler P, Patel MK (1991) Development and evaluation of the Osteoporosis Health Belief Scale. Res Nurs Health 14(2):155–163PubMedCrossRef
60.
go back to reference Magkos F, Manios Y, Babaroutsi E, Sidossis LS (2006) Development and validation of a food frequency questionnaire for assessing dietary calcium intake in the general population. Osteoporos Int 17(2):304–312PubMedCrossRef Magkos F, Manios Y, Babaroutsi E, Sidossis LS (2006) Development and validation of a food frequency questionnaire for assessing dietary calcium intake in the general population. Osteoporos Int 17(2):304–312PubMedCrossRef
61.
go back to reference Godin G (1997) Godin leisure-time exercise questionnaire. Med Sci Sports Exerc 29(June Supplement):S36–S38 Godin G (1997) Godin leisure-time exercise questionnaire. Med Sci Sports Exerc 29(June Supplement):S36–S38
62.
go back to reference Arkowitz H, Westra HA (2009) Introduction to the special series on motivational interviewing and psychotherapy. J Clin Psychol 65(11):1149–1155PubMedCrossRef Arkowitz H, Westra HA (2009) Introduction to the special series on motivational interviewing and psychotherapy. J Clin Psychol 65(11):1149–1155PubMedCrossRef
63.
go back to reference Dunniway DL, Camune B, Baldwin K, Crane JK (2012) FRAX(R) counseling for bone health behavior change in women 50 years of age and older. J Am Acad Nurse Pract 24(6):382–389PubMedCrossRef Dunniway DL, Camune B, Baldwin K, Crane JK (2012) FRAX(R) counseling for bone health behavior change in women 50 years of age and older. J Am Acad Nurse Pract 24(6):382–389PubMedCrossRef
Metadata
Title
The impact of bone mineral density testing, fracture assessment, and osteoporosis education in men treated by androgen deprivation for prostate cancer: a pilot study
Authors
Michelle Nadler
Shabbir Alibhai
Pamela Catton
Charles Catton
Jennifer Jones
Publication date
01-09-2014
Publisher
Springer Berlin Heidelberg
Published in
Supportive Care in Cancer / Issue 9/2014
Print ISSN: 0941-4355
Electronic ISSN: 1433-7339
DOI
https://doi.org/10.1007/s00520-014-2183-6

Other articles of this Issue 9/2014

Supportive Care in Cancer 9/2014 Go to the issue
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine